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Natural killer (NK) cell efﬁcacy correlates with in vivo proliferation, and we hypothesize that NK cell product
manipulations may optimize this endpoint. Xenotransplantation was used to compare good manufacturing
practice (GMP) grade freshly activated NK cells (FA-NK) and ex vivo expanded NK cells (Ex-NK). Cells were
infused into NOD scid IL2 receptor gamma chain knockout (NSG) mice followed by IL-2, IL-15, or no cytokines.
Evaluation of blood, spleen, and marrow showed that persistence and expansion was cytokine dependent, IL-
15 being superior to IL-2. Cryopreservation and immediate infusion resulted in less cytotoxicity and fewer NK
cells in vivo, and this could be rescued in FA-NK by overnight culture and testing the next day. Marked
differences in the kinetics and homing of FA-NK versus Ex-NK were apparent: FA-NK cells preferentially
homed to spleen and persisted longer after cytokine withdrawal. These data suggest that cryopreservation of
FA-NK and Ex-NK is detrimental and that culture conditions profoundly affect homing, persistence, and
expansion of NK cells in vivo. The NSG mouse model is an adjuvant to in vitro assays before clinical testing.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Natural killer (NK) cells recognize targets altered by ma-
lignant transformation or infection. The ﬁrst trials in humans
to harness the antitumor properties of NK cells focused on
the use of in vivo IL-2 to activate autologous NK cells. Ex vivo
IL-2 activation of NK cells before infusion resulted in
enhanced recovery of NK cell cytotoxicity in vivo compared
with postinfusion IL-2 administration alone, but efﬁcacy was
probably limited by (1) competition with the recipient’s
lymphocytes for cytokines and “space,” (2) inhibition of
autologous NK cells by self MHC, and (3) chronic immuno-
suppression induced by the tumor on host immunity. As
inhibitory killer cell Ig-like receptor (KIR) and their ligands
were further characterized, the next approach to using NK
cells as immunotherapy focused on allogeneic NK cells from
healthy related donors. In this setting, allogeneic NK cellsedgments on page 1257.
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being educated and fully functional.
The ﬁrst trial of this approach was published in 2005
from the University of Minnesota [1]. Forty-three patients
with metastatic melanoma, metastatic renal cell carcinoma,
or poor prognosis acute myelogenous leukemia were
enrolled. Peripheral blood (PB) was collected by apheresis
from haploidentical related donors, and NK cells were
enriched before being incubated overnight in high-dose IL-
2. Before NK cell infusion, patients underwent 1 of 3
chemotherapy preparative regimens: high cyclophospha-
mide and ﬂudarabine that was potently lymphodepleting or
a lower intensity regimen of either low-dose cyclophos-
phamide and methylprednisone or ﬂudarabine alone. After
infusion, patients received IL-2 daily for 14 days or 3 times
per week (or for 6 doses). NK cell persistence was only
observed in acute myelogenous leukemia patients receiving
the lymphodepleting preparatory regimen of high cyclo-
phosphamide and ﬂudarabine. On this initial protocol 30%
of poor prognosis acute myelogenous leukemia patients
achieved a complete remission, which correlated with the
presence of donor NK cells 7 and 14 days after infusion.
Based on this, goals to improve NK cellebased immuno-
therapy have focused on in vivo expansion as a surrogate
biomarker to enhance efﬁcacy. Cytokine choice may play a
role in NK cell expansion. Although in vivo NK cell expan-
sion is enhanced by cytokines, IL-2 can also stimulate
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[4,5].
In an alternative approach to enhance in vivo expansion,
Lapteva et al. [6] developed ex vivo good manufacturing
practice (GMP)-compatible NK cell expansion strategies
based on the use of K562 feeders transducedwithmembrane
bound IL-15 and 41BB-ligand initially described by Imai et al.
[7]. It is unknownwhether freshly isolated NK cells followed
by postinfusion cytokines (in vivo NK cell expansion) or
ex vivo expansion strategies or both are the best to achieve
efﬁcacy, the goal of clinical trials. In vitro functional assays
are of limited use to address this endpoint. Therefore, the
goal of this study was to use a xenogeneic adoptive transfer
model to examine the impact of clinical NK cell production
methods and postinfusion cytokine administration on in vivo
NK cell expansion. It is our hope that these results will guide
the design of effective cancer therapies using NK cells.
METHODS
NK Cell Isolation, Processing, and Functional Testing
All studies were in accordance with the Declaration of Helsinki and
guidelines approved by the Committees on the Use of Human Subjects and
Animals in Research. Nonmobilized apheresis products were collected from
the University of Minnesota and Baylor College of Medicine. For production
of freshly activated NK cells (FA-NK), NK cells were enriched from mono-
nuclear cells by CD3þ and CD19þ cell depletion (Miltenyi Biotec, Bergisch
Gladbach, Germany) followed by overnight IL-2 (Proleukin, 1000 U/mL;
Prometheus, San Diego, CA) incubation under cGMP [8]. Ex vivo expanded
NK cells (Ex-NK) were generated by culture of buffy coat mononuclear cells
with K562 cells expressing membrane bound IL-15 and 41BB-L and 10 U/mL
IL-2 in G-Rex (Wilson Wolf, Minneapolis, MN) chambers for 10 days. On the
day before shipping, contaminating CD3þ cells were removed [6]. NK cells
were split and either infused directly or cryopreserved in 10% DMSO and
then thawed, recounted, and injected. NK cells were tested for function
using a Cr51 release assay with K562 targets or by ﬂow cytometry [9,10].
Xenogeneic NK Cell Adoptive Transfer
NOD scid IL2 receptor gamma chain knockout (NSG) mice were given
250 cGy total body irradiation by x-ray and infused i.v. with 1 to 2 million
fresh or frozen NK cells. Mice were left untreated or were given 5 or 10 mg
huIL-2 Prometheus or 5 mg huIL-15 (NCI-Frederick, MD) in 6 i.p. injections
over 2 weeks. PB, spleen, and marrow were evaluated after adoptive
transfer. Human NK cell counts were converted to absolute cell numbers per
indicated volume of blood or the number of cells recovered per spleen or
after ﬂushing both femurs. For comparisons, a Student’s t-test was usedwith
paired analysis where appropriate.
Flow Cytometry
Blood or tissue were stained according to standard protocols. The
following antibodies were used: CD45 Horizon V500, CD56 PE-Cy7, and
CD158b FITC (clone CH-L) from BD Biosciences (San Jose, CA); CD3 PE-Texas
Red from Life Technologies (Carlsbad, CA); NKG2A allophycocyanin from
Beckman Coulter; CD158a PerCP-Cy5.5 (clone HP-MA4) from eBioscience
(San Diego, CA); NKG2C Phycoerythrin from R&D Systems (Minneapolis,
MN); and CD57 Paciﬁc Blue and CD158e1 Alexa Fluor 700 (clone DX9) from
Biolegend (San Diego, CA).
RESULTS
We propose that NK cell product manipulations may
optimize in vivo proliferation to provide better therapy for
treatment of cancer. Two GMP-grade NK cells products
produced by different Production Assistance for Cellular
Therapies facilities were evaluated: FA-NK, used by the
Minnesota group for the past 10 years, and Ex-NK, devel-
oped as a GMP product by the Baylor College of Medicine
group [6]. Ex-NK contained a higher proportion of CD56þ/
CD3 NK cells compared with FA-NK cells, which contained
monocytes, but when effector-to-target ratios in the Cr51
release killing assay were normalized to NK cell frequency,
the killing at each effector-to-target ratio was similar
(Figure 1A). Phenotypically there were differences betweenthe cell products (Figure 1A). Ex-NK had a lower proportion
of the homing receptor CD62L, possibly related to
activation-induced shedding of CD62L [11], and a lower
proportion of the mature CD57þ cells, likely explained by
the higher proliferative rate of less mature CD57 negative
cells [12,13]. Compared with FA-NK, Ex-NK also had higher
levels of the NKG2A inhibitory receptor and HLA-DR, likely
due to a longer culture period.
We ﬁrst transferred fresh and frozen Ex-NK and FA-NK
cells followed by IL-2 administration (5-mg dose) and deter-
mined the kinetics of NK cell expansion and persistence.
Given the differences in the composition of the cell products,
each product was adjusted so the same absolute number
of CD56þCD3 NK cells was infused. We evaluated the
cytokine-dependent expansion phase (days 0 to 14) and a
cytokine withdrawal phase (days 14 to 28) mimicking the
proposed dosing strategy used in patients [2], as indicated in
the schema in Figure 1B. NK cells were present at day 7 after
adoptive transfer for both fresh Ex-NK and FA-NK cells, but
there was no in vivo expansion for either product between
days 7 and 14 with IL-2 administration (Figure 1C). Despite
immediate rate-controlled freezing using clinical methods
and high viability post-thaw (Ex-NK were 93% viable post-
thaw; FA-NK were 92% viable post-thaw), cryopreserved
NK cells that were thawed and immediately infused were
found in much smaller numbers in vivo than fresh cells from
both products, suggesting they are sensitive to stress im-
mediately after thawing.
We then compared the cytokine dependence of each NK
cell product, giving 5 mg (not shown) or 10 mg IL-2, 5 mg of
IL-15, or no cytokines in each of the 6 doses (Figure 1D).
Seven days after adoptive transfer, there were signiﬁcantly
more NK cells recovered from mice given the Ex-NK versus
FA-NK product and IL-15 (comparing day 7 Ex-NK to FA-NK:
P ¼ .03). IL-15, but not IL-2, resulted in a signiﬁcant increase
in NK cells between days 7 and 14 in mice given either NK
product (comparing day 7 with day 14 for each product in
mice given IL-15, Ex-NK: P ¼ .004; FA-NK: P ¼ .00004). These
results demonstrate the dependence of NK cell persistence
and expansion on exogenous cytokine administration with
IL-15 being more potent than IL-2. Importantly, NK cells
recovered on day 14 from the blood of mice given IL-15 and
both products were functional, as indicated by their ability to
degranulate and produce IFN-g after exposure to K562 tar-
gets (not shown). Mice sampled on day 21, 1 week after the
ﬁnal cytokine dose, showed a loss of NK cells in PB. Ex-NK
cells from mice given IL-15 showed a 90% decrease in
numbers, whereas FA-NK cells decreased by only 45%. One
explanation for this difference may be greater cytokine
“addiction” of the Ex-NK cells [14,15]. Alternatively, different
migration patterns may explain these differences.
Given the potent effect of in vivo IL-15, we next examined
the ability of thawed NK cells to expand in vivo with IL-15.
We tested Ex-NK and FA-NK that were infused immediately
after thawing or after overnight culture with IL-2 in an
attempt to improve in vivo survival of cryopreserved cells.
We evaluated cytotoxicity against K562 targets immediately
after the thaw and after the overnight culture (Figure 2A).
Both Ex-NK and FA-NK were weakly cytotoxic immediately
after thaw and both recovered cytotoxic activity after culture
with overnight IL-2. Viabilities of both products were high
after thawing (Ex-NK: 89%; FA-NK: 90%); however, only 20%
of Ex-NK cells remained after overnight culture, whereas 73%
of FA-NK cells survived. Equal numbers of viable Ex-NK and
FA-NK cells, both immediately post-thaw and after overnight
Figure 2. Thawed GMP grade Ex-NK and FA-NK cells expand in vivo when cultured overnight with IL-2 before adoptive transfer. Ex-NK and FA-NK products were
thawed after cryopreservation in 10% DMSO and transferred to NSG mice either immediately (Thaw/inject) or after overnight culture with IL-2 (O/N IL-2). All mice
were subsequently given 6 doses of IL-15 at 5 mg/dose. (A) Cytotoxic activity of each product is shown as the percent of Cr51-labeled K562 cells lysed when incubated
for 4 hours with each product at the indicated ratios. (B) The number of human CD45þ NK cells in 150 mL of blood collected on days 7 and 14 after transfer. Results
shown are the means  SEM, n ¼ 6 mice per group.
Figure 1. GMP grade Ex-NK cells and FA-NK cells differ in phenotype and their ability to expand in mice in vivo. (A) The Ex-NK cell product contained an average of
88% NK cells, whereas the FA-NK cell product contained 40% NK cells after CD3 and CD19 depletion, with the remaining cells being CD14þ monocytes (not shown).
Inset shows percent of Cr51-labeled K562 cells lysed when incubated for 4 hours with Ex-NK or FA-NK cells at the indicated ratios. (B) NSG mice were treated with
250 cGy and then Ex-NK or FA-NK cells (1 to 2 million absolute NK cells were held constant within each experiment) were infused i.v. Cytokines were administered
after cell infusion as indicated. Blood was sampled weekly and tissues collected as indicated. (C) The number of human CD45þ NK cells in 100 mL of blood collected at
the various times after transfer of Ex-NK or FA-NK cells obtained either directly from in vitro cultures (fresh) or thawed after cryopreservation in 10% DMSO (frozen).
All mice were given IL-2 (6 doses, 5 mg/dose). Data are means  SEM (n ¼ 4). (D) The number of human CD45þ NK cells in 100 mL of blood collected at the indicated
times after transfer of Ex-NK or FA-NK from fresh cultures. Mice were given cytokines as indicated; IL-2 was given in 6 doses of 10 mg/dose; IL-15 was given in 6 doses
of 5 mg/dose. Data are means  SEM (n ¼ 6 to 16, depending on time point and group, as selected mice were killed 8 or 15 days after cell infusion).
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(6 doses of 5 mg/dose), and PBwas evaluated on days 7 and 14
for the presence of human NK cells (Figure 2B). NK cells that
were injected immediately after thaw were found in slightly
higher numbers in mice given IL-15 (Figure 2B) than in mice
given IL-2 (Figure 1D). Overnight culture of thawed Ex-NK
cells before transfer resulted in only a slight increase in the
number of humanNK cells found in the blood on days 7 or 14.
This was not surprising because most Ex-NK cells did not
survive the overnight culture; therefore, further optimiza-
tion of rescue culture conditions for this product are needed
to improve subsequent survival in vivo. In contrast, thawed
and cultured FA-NK cells expanded to a similar extent as
fresh FA-NK cells in mice given IL-15 (Figure 1D).
Because there were differences in the phenotype of the 2
NK products before adoptive transfer, we examined the
phenotype of human NK cells in PB to determine if it would
change over time or with different cytokine conditions. We
found the fraction of NK cells that expressed any of 3 KIRs
remained stable (Figure 3A) as well as the fraction expressing
each individual KIR (data not shown). The percent of Ex-NK
cells that expressed NKG2A was high before transfer and
remained high while either IL-2 or IL-15 was being given and
1 week after cytokine withdrawal (Figure 3B). NKG2A
expression was less on FA-NK cells than on Ex-NK cells
before adoptive transfer. In mice given FA-NK cells followed
by IL-2, the average percent of NKG2A expression remainedFigure 3. Phenotype of GMP grade Ex-NK and FA-NK cells in the blood varies with
Figure 1D. (A) Percent of human NK cells expressing any of 3 KIRs (CD158a, CD158b,
human NK cells expressing CD57. Results shown are the means  SD (n ¼ 7 to 16, dconstant during the period of cytokine delivery. In contrast,
in mice given FA-NK cells and IL-15, the percent of NK cells
that were NKG2A positive increased by day 7 in all 16 mice
and continued to increase through day 14 (P ¼ .017 by paired
t-test). The average frequency of NKG2Aþ cells decreased
1 week after withdrawal of either cytokine in mice given FA-
NK cells, although this was only signiﬁcant in mice given IL-
15 (P¼ .1 for mice given IL-2; P< .001 for mice given IL-15 by
paired t-test). These results indicate that high NKG2A
expression is a characteristic of the ex vivo expanded product
and remains stable after adoptive transfer and different
cytokine conditions, whereas NKG2A expression on FA-NK
cells is more responsive to IL-15.
CD57 is a marker of terminal maturation on NK cells
[12,13] and was expressed on a much smaller percentage of
Ex-NK cells than FA-NK cells (9.4% and 45.8% CD57þ,
respectively) before adoptive transfer. We measured CD57
expression on the transferred NK cells in PB over time and
found that expression on FA-NK cells was unchanged in mice
given either IL-2 or IL-15 but increased signiﬁcantly on Ex-
NK cells in response to either cytokine (Figure 3C). Because
Ex-NK cells are highly cytokine dependent, we were only
able to evaluate CD57 expression in the absence of exoge-
nous cytokine on day 7 after transfer (data not shown). At
that time the frequency of CD57þNK cells was higher in 12 of
16 mice compared with the pretransfer percentage, with an
average of 18%, whereas all mice given either IL-2 or IL-15NK cell source and cytokine conditions. Cells and mice were as described in
or CD158e1). (B) Percent of human NK cells expressing NKG2A. (C) Percent of
epending on time point and group).
Figure 4. GMP grade Ex-NK and FA-NK cells have different biodistribution in bone marrow and spleen. (A) The number of human NK cells in bone marrow and spleen
of mice given Ex-NK or FA-NK cells and cytokines as shown in Figure 1B. (B) The percent of proliferating (as evidenced by coexpression of Ki-67 on CD56þ/CD3- cells)
human NK cells 8 days after adoptive transfer of Ex-NK or FA-NK cells in bone marrow or spleen, respectively. (C) The proportion of CD57þ human NK cells 8 (left) and
15 (right) days after adoptive transfer of Ex-NK or FA-NK cells in bone marrow or spleen, respectively. Data are mean  SE for all analyses (n ¼ 4). Where indicated,
P values were determined using an unpaired t-test to compare results for bone marrow and spleen within a treatment group.
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transfer value and an average of 33% CD57þ in each group.
These results suggest that while in vivo transfer alone may
have some effect on CD57 expression, the addition of cyto-
kines drives additional increases in CD57 expression on
Ex-NK cells in vivo.
For immune cells to be efﬁcacious, they must achieve
favorable biodistribution into sites of tumor. Thus, we eval-
uated tissue recovery of human NK cells in groups of mice at
day 8 (Figure 4A) and day 15 (data not shown) after adoptive
transfer. In the absence of cytokine administration, NK cells
were barely detectable in blood or tissues. Mice given Ex-NK
cells and IL-15 had higher numbers of NK cells in onemarrow
than mice given Ex-NK cells and IL-2; conversely, mice that
received FA-NK cells had more NK cells in the spleen when
given IL-15, showing dramatic homing differences between
the 2 cell products. After adoptive transfer, more Ki-67þ
proliferating NK cells were found in bone marrow than
spleen; the differences were signiﬁcant for both products in
IL-15etreated mice (Figure 4B). Finally, CD57 was expressed
bymoreNK cells recovered fromspleen than bonemarrowon
day 8 for the Ex-NK product (Figure 4C, left), and the pref-
erential accumulation in the spleen of terminally differenti-
ated CD57þ NK cells, presumed to exhibit maximal effector
function, was further enhanced on day 15 for both products
(Figure 4C, right). Expression of CD57 in the spleen mirrored
closely the expression on NK cells in the blood (Figure 3C).
The preferential homing of Ex-NK cells to bone marrow and
the lower expression of CD57 on Ex-NK cells suggest that
CD57 expression could be a predictor of in vivo trafﬁcking
preference, at least for spleen compared with bone marrow.DISCUSSION
NK cells have potent antitumor activity when they are not
constrained by class Ierecognizing inhibitory receptors. They
are particularly attractive as therapeutic effectors because
they do not cause graft-versus-host disease and they can be
selected therapeutically using available GMP reagents. One
challenge of NK cell therapy is how to optimize the effector-
to-target ratio dose that is critical for cytotoxicity and ulti-
mately clinical efﬁcacy. Two approaches have been tested to
increase NK cell numbers in an attempt to promote anti-
tumor efﬁcacy. One strategy is aimed at in vivo expansion of
adoptively transferred NK cells that can be obtained with a
single apheresis product (1 to 2  107 NK cells/kg). The
success of this strategy depends on a lymphodepleting
chemotherapy regimen. One of the complexities of this
therapy is that in vivo expansion is achieved in a low number
of patients. It may be that cancer patients have the ability to
reject rapidly adoptively transferred cells or that the cancer
itself directly inhibits NK cell immunity. An alternative
approach is to expand NK cells ex vivo to markedly increase
the number of infused cells by use of K562 stimulators
transduced with 41BB-ligand and IL-154 or IL-21 [16] or the
use of lymphoblastoid cell line targets [17]. Compared with
resting cells, these expanded NK cells change receptors
important in activation pathways needed for cytokine pro-
duction and cytotoxicity. However, cytokine withdrawal
may be detrimental to cell function. As one contemplates
comparative studies between in vivo and ex vivo expansion
approaches, several questions need to be answered. Cells that
are activated may change shape and adhesion receptor pro-
ﬁles. How this affects homing and targeting to tumors is not
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expansion of NK cells in vivo or ex vivo may lead to better
survival and persistence, the goal of our study.
This xenogeneic model provides deﬁnitive readouts with
distinct characteristics of FA-NK and Ex-NK cell products
that may inform clinical efﬁcacy. Common to both products
is the profound negative impact of cryopreservation. This can
be rescued in FA-NK by thawing and overnight culture with
IL-2. However, the same strategy used on Ex-NK was signif-
icantly less effective for that product, suggesting other
methods are needed. There was a signiﬁcant beneﬁt of IL-15
to support in vivo proliferation of NK cells in vivo after
adoptive transfer from both products. We ﬁnd that better
in vivo expansionwith IL-15 leads to enhanced expression of
NKG2A on NK cells in vivo, consistent with the activation-
dependent expression of this inhibitory receptor, which is
also increased early after hematopoietic transplantation. For
tumors that highly express HLA-E, high expression [18] of
this inhibitory receptor may not be optimal, but this needs to
be tested clinically.
These considerations are important because IL-15 is being
developed clinically and is currently in phase I clinical trials.
The rapid loss of Ex-NK cells between days 14 and 21 after
IL-15 withdrawal compared with FA-NK cells emphasizes the
importance of continued cytokine stimulation for ex vivo
expanded cells. In addition to kinetic differences, we identify
different homing properties after infusion for the 2 NK cell
products. Our ﬁndings support the possibility that different
properties of NK cell products may be exploited to treat
cancer in the marrow or spleen, but this will require
comparative clinical trials. It is still unknown whether pref-
erential homing has any relevance in eradicating tumor.
Adapting this strategy in tumor-bearing mice will be studied
in the future to more deﬁnitely test these approaches.
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